In conclusion, our study highlights the application of ARRDC1–p53 (ARP) and CD63–p53 (CDP) fusion constructs in augmenting the functionality of cell-derived sEVs, showcasing enhanced p53 mRNA and protein enrichment in sEVs, alongside superior anti-tumor efficacy. This evidence concerns the gene TP53 and neoplasm.